Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Anticancer Research|August 5, 2010
Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075Ching-Ping Chen, Chih-Bo Hu, Kai-Chia Yeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatmentJen-Shin Song, Chih-Chun Chang, Chien-Huang Wu, et al.
Journal of Medicinal Chemistry|June 11, 2019
Linker Optimization and Therapeutic Evaluation of Phosphatidylserine-Targeting Zinc Dipicolylamine-based Drug ConjugatesYu-Wei Liu, Yun-Yu Chen, Chia-Yu Hsu, et al.
Journal of Medicinal Chemistry|June 14, 2017
Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase InhibitorsTeng-Kuang Yeh, Ching-Chuan Kuo, Yue-Zhi Lee, et al.
Bioorganic Chemistry|March 16, 2020
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitorsShu-Yu Lin, Chun-Feng Chang, Mohane Selvaraj Coumar, et al.
Journal of Medicinal Chemistry|May 20, 2025
Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC HelixYi-Hui Peng, Mu-Chun Li, Wan-Ching Yen, et al.
Journal of Medicinal Chemistry|January 10, 2018
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and BeyondChien-Huang Wu, Jen-Shin Song, Hsuan-Hao Kuan, et al.
European Journal of Medicinal Chemistry|June 18, 2015
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutationsChiung-Tong Chen, John T-A Hsu, Wen-Hsing Lin, et al.
Pageof 13